 |
52 Diseases |  |
106 Trials |
|
106 Trials |  |
1280 News |  |
| «12...10111213141516171819202122» |
- |||||||||| Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
New P3 trial: PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 22, 2014
P3, N=300, Not yet recruiting, Sponsor: Celltrion
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - May 18, 2014
P1, N=33, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2014 --> Dec 2014
- | New P2 trial: MPAL: Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia (clinicaltrials.gov) - May 8, 2014
P2, N=60, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Rituxan (rituximab) / Roche
Trial primary completion date: Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma (clinicaltrials.gov) - May 1, 2014
P1/2, N=81, Recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Jan 2014 --> Dec 2014 Trial primary completion date: Jan 2015 --> Jan 2016
- Rituxan (rituximab) / Roche
Trial completion date: Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma (clinicaltrials.gov) - May 1, 2014
P1/2, N=81, Recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Jan 2015 --> Jan 2016 Trial completion date: Jan 2016 --> Jan 2017
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Apr 16, 2014
P1/2, N=73, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial completion date: Jan 2016 --> Jan 2017 Not yet recruiting --> Recruiting
- ||| Rituxan (rituximab) / Roche
Enrollment change: Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia (clinicaltrials.gov) - Mar 31, 2014
P2, N=150, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting N=74 --> 150
- |||| Rituxan (rituximab) / Roche
Enrollment open: Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia (clinicaltrials.gov) - Mar 31, 2014
P2, N=150, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=74 --> 150 Active, not recruiting --> Recruiting
- || Rituxan (rituximab) / Roche
Enrollment closed: NCI-2018-01851: Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma (clinicaltrials.gov) - Mar 13, 2014
P1, N=110, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
IO biomarker: ECOG-ACRIN E1912: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Mar 10, 2014
P3, N=519, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Roche
Enrollment closed: Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Mar 4, 2014
P1/2, N=95, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P3 trial, IO biomarker: ECOG-ACRIN E1912: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Jan 27, 2014
P3, N=519, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: ALLIANCE A041202: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 22, 2014
P3, N=523, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 5, 2014
P3, N=360, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open: Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Dec 16, 2013
P2, N=208, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P2 trial: Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Dec 8, 2013
P2, N=208, Recruiting, Sponsor: M.D. Anderson Cancer Center
- | Blincyto (blinatumomab) / Astellas, Amgen
New P3 trial: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 4, 2013
P3, N=360, Recruiting, Sponsor: National Cancer Institute (NCI)
- Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku, Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Enrollment closed: NCI-2011-00344: Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 25, 2013
P1/2, N=57, Active, not recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | cerdulatinib (ALXN2075) / Nicox, AstraZeneca
New P1 trial: Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL (clinicaltrials.gov) - Nov 21, 2013
P1, N=28, Recruiting, Sponsor: Portola Pharmaceuticals
- Torisel (temsirolimus) / Pfizer, Rituxan (rituximab) / Roche
Enrollment open: Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma (clinicaltrials.gov) - Nov 17, 2013
P1/2, N=144, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Suspended --> Recruiting
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: ALLIANCE A041202: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Oct 27, 2013
P3, N=523, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Initiation date: Jul 2013 --> Oct 2013
- ||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 17, 2013
P2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Jul 2013 --> Oct 2013 Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Oct 8, 2013
P1/2, N=73, Recruiting, Sponsor: Roswell Park Cancer Institute
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Aug 29, 2013
P2, N=300, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
Trial completion, Combination therapy: A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects (clinicaltrials.gov) - Aug 21, 2013
P1, N=186, Completed, Sponsor: Teva Pharmaceutical Industries
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open: Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Jul 14, 2013
P2, N=50, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - Jun 27, 2013
P1, N=33, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P3 trial: ALLIANCE A041202: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jun 24, 2013
P3, N=523, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P2 trial: Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Jun 17, 2013
P2, N=50, Recruiting, Sponsor: M.D. Anderson Cancer Center
- ||| Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
New P1 trial: Long-Term Efficacy and Safety of CT-P10 in Patients With RA (clinicaltrials.gov) - Jun 6, 2013
P1, N=102, Enrolling by invitation, Sponsor: Celltrion
- Rituxan (rituximab) / Roche
Enrollment open: Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma (clinicaltrials.gov) - May 19, 2013
P=N/A, N=80, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Rituxan (rituximab) / Roche
New P2 trial: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - May 15, 2013
P2, N=300, Recruiting, Sponsor: National Cancer Institute (NCI)
- ||| Rituxan (rituximab) / Roche
Enrollment closed, Metastases: Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma (clinicaltrials.gov) - May 15, 2013
P2, N=120, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku, Rituxan (rituximab) / Roche
Enrollment open: NK Cells in Cord Blood Transplantation (clinicaltrials.gov) - May 2, 2013
P1, N=13, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P1 trial: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - Apr 9, 2013
P1, N=33, Recruiting, Sponsor: National Cancer Institute (NCI)
- ||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed: Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant (clinicaltrials.gov) - Mar 28, 2013
P2, N=52, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Roche
Enrollment closed: Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant (clinicaltrials.gov) - Mar 25, 2013
P1, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
Enrollment closed: Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 18, 2013
P1, N=147, Active, not recruiting, Sponsor: Celltrion
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Rituxan (rituximab) / Roche
Enrollment change: NCI-2018-01851: Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma (clinicaltrials.gov) - Feb 13, 2013
P1, N=110, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=90 --> 110
- ||| Rituxan (rituximab) / Roche
Enrollment closed, Combination therapy: NCI-2018-01853: Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov) - Feb 4, 2013
P2, N=155, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=90 --> 110 Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Roche, Yervoy (ipilimumab) / BMS
Enrollment open, Combination therapy: Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Jan 10, 2013
P1, N=38, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Roche, Yervoy (ipilimumab) / BMS
New P1 trial, Combination therapy: Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Nov 18, 2012
P1, N=38, Recruiting, Sponsor: National Cancer Institute (NCI)
- Rituxan (rituximab) / Roche
Enrollment closed: SWOG-C10404: Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Oct 29, 2012
P2, N=405, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Besponsa (inotuzumab ozogamicin) / Pfizer, Rituxan (rituximab) / Roche
Enrollment open: NCI-2012-02072: CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies (clinicaltrials.gov) - Oct 28, 2012
P1/2, N=30, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment open: Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma (clinicaltrials.gov) - Oct 25, 2012
P1/2, N=80, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Roche
Enrollment change: Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma (clinicaltrials.gov) - Oct 22, 2012
P=N/A, N=80, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting N=100 --> 80
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
New P1/2 trial: Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma (clinicaltrials.gov) - Oct 3, 2012
P1/2, N=80, Recruiting, Sponsor: M.D. Anderson Cancer Center
- alisertib (MLN8237) / Puma, Rituxan (rituximab) / Roche
New P1 trial, Combination therapy: Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (clinicaltrials.gov) - Sep 26, 2012
P1, N=24, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Besponsa (inotuzumab ozogamicin) / Pfizer, Rituxan (rituximab) / Roche
New P1/2 trial: NCI-2012-02072: CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies (clinicaltrials.gov) - Aug 12, 2012
P1/2, N=30, Recruiting, Sponsor: M.D. Anderson Cancer Center
- Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
Enrollment open, Combination therapy: Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial (clinicaltrials.gov) - Jul 31, 2012
P1, N=10, Recruiting, Sponsor: Celltrion
N=100 --> 80 Not yet recruiting --> Recruiting